Intersect ENT, Inc. (XENT) Hits New 12-Month High at $32.30
Intersect ENT, Inc. (NASDAQ:XENT)’s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $32.30 and last traded at $32.30, with a volume of 107,119 shares. The stock had previously closed at $31.75.
A number of equities analysts recently issued reports on XENT shares. Zacks Investment Research lowered shares of Intersect ENT from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. ValuEngine raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Northland Securities lowered shares of Intersect ENT from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 31st. BidaskClub lowered shares of Intersect ENT from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Finally, Deutsche Bank AG set a $31.00 target price on shares of Intersect ENT and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Intersect ENT currently has a consensus rating of “Buy” and a consensus price target of $24.88.
The company’s 50 day moving average is $29.87 and its 200 day moving average is $23.38. The stock’s market cap is $928.21 million.
Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.11. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The company had revenue of $24 million for the quarter, compared to analysts’ expectations of $22.62 million. During the same quarter last year, the business earned ($0.21) earnings per share. Intersect ENT’s revenue was up 24.4% on a year-over-year basis. Analysts expect that Intersect ENT, Inc. will post ($0.61) earnings per share for the current fiscal year.
In related news, CFO Jeryl L. Hilleman sold 12,833 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $31.05, for a total value of $398,464.65. Following the sale, the chief financial officer now directly owns 27,833 shares of the company’s stock, valued at $864,214.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Lisa D. Earnhardt sold 20,000 shares of the firm’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $26.10, for a total value of $522,000.00. Following the completion of the sale, the insider now directly owns 583,493 shares in the company, valued at $15,229,167.30. The disclosure for this sale can be found here. Insiders sold 133,426 shares of company stock worth $3,868,685 in the last 90 days. 13.70% of the stock is owned by company insiders.
A number of large investors have recently added to or reduced their stakes in XENT. FMR LLC boosted its stake in Intersect ENT by 247.7% in the second quarter. FMR LLC now owns 1,482,909 shares of the medical equipment provider’s stock valued at $41,447,000 after buying an additional 1,056,389 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Intersect ENT by 2,746.9% in the second quarter. Alliancebernstein L.P. now owns 931,505 shares of the medical equipment provider’s stock valued at $26,036,000 after buying an additional 898,785 shares in the last quarter. Paulson & CO. Inc. acquired a new stake in Intersect ENT in the first quarter valued at about $10,978,000. Lord Abbett & CO. LLC acquired a new stake in Intersect ENT in the second quarter valued at about $9,384,000. Finally, Marshall Wace LLP acquired a new stake in Intersect ENT in the first quarter valued at about $5,129,000. 83.12% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Intersect ENT, Inc. (XENT) Hits New 12-Month High at $32.30” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/08/intersect-ent-inc-xent-hits-new-12-month-high-at-32-30.html.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.